December 2023 Update: BioGX in silico analysis of SARS-CoV-2 variants of interest and emerging variants

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants.

BioGX has completed in silico analysis of over 290,000 complete high coverage Omicron genomes of sublineages belonging to the JN.1, EG.5, BA.2.86, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, and JG.3 clades present in the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV™ database as of 31 December, 2023 (Table 1). Sequence analysis of the variant genomes was compared against the SARS-CoV-2 reference genome to identify any mutations within the regions of the nucleocapsid (N-gene), membrane (M-gene), and the coding region of the ORF1a gene (RdRp) targeted by BioGX products.

Based on in silico analysis and empirical testing, the nucleotide mutations present in the JN.1, EG.5, BA.2.86, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, and JG.3 clades at the time of this analysis will not affect the detection capability of the BioGX portfolio of SARS-CoV-2 products and all variants analyzed will be detected.

BioGX continues to monitor emerging SARS-CoV-2 lineage variants and any mutations with the potential to impact performance.

Table 1. Number of sequences analyzed for each Omicron sublineage available from GISAID as of 31 December 2023.

Omicron Sublineages Analyzed by BioGX

Omicron sublineage Nextstrain clade Emergence Location (Date) No. Sequences Present and Analyzed

(as of 31DEC2023)

JN.1 23I Luxembourg / Iceland (AUG 2023) 15,548
EG.5 23D Denmark
(JUL 2023)
BA.2.86 21L Denmark
(JUL 2023)
XBB.1.5 23A USA (OCT 2022) 172,673
XBB.1.16 23B USA (JAN 2023) 33,318
HV.1 23F China (JAN 2023) 30,422
HK.3 23H USA (OCT 2022) 22,572
JD.1.1 23A USA (JUL 2023) 7,601
JG.3 23F France (JUL2023) 8,370

BioGX Expands PCR Test Menu at State Departments of Health

BIRMINGHAM, AL / January 11, 2024 / BioGX, a leading global provider of easy molecular diagnostic solutions, is pleased to announce the test menu expansion support to Departments of Health (DoH) with the addition of its Candida auris assay. BioGX currently services 6 DoH agencies with expansion to 10 agencies expected in Q1 2024.

“We are excited to support the state Departments of Health by providing menu expansion solutions to meet stringent assay performance requirements,” said Shahin Iqbal, PhD, BioGX President & COO. “Our goal is to empower healthcare professionals with the best tools available, and this expansion is a testament to our commitment to improving public health outcomes in the region.”

As healthcare continues to evolve, the importance of robust and accurate diagnostic solutions has never been more critical. BioGX is committed to providing innovative and reliable molecular diagnostics solutions to support public health initiatives. State health departments play a pivotal role in safeguarding public health, requiring cutting-edge molecular diagnostics to quickly respond to the ever-changing landscape of testing needs.

View Original Press Release at: